Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 4 | BMC Cancer

Fig. 4

From: Vascular disruptive agent OXi4503 and anti-angiogenic agent Sunitinib combination treatment prolong survival of mice with CRC liver metastasis

Fig. 4

Changes in tumor proliferation following different treatment regimens. a Formalin fixed liver sections with CRC liver metastases were stained for the proliferation marker KI67. First column Scale bar = 200 μm. Second column represents area within the inset of the first column at a higher magnification. Scale bar = 50 μm. b enumeration of proliferating cells *P < 0.003, combination vs OXi4503 and # P < 0.016, combination vs Sunitinib. Data was not normally distributed and non-parametric analysis was performed and statistical significance determined using Mann-Whitney U test

Back to article page